OUT OF MIND
Would you like to react to this message? Create an account in a few clicks or log in to continue.
Latest topics
» Gas Prices Hit $4 A Gallon In Every State For First Time
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 11:42 am by PurpleSkyz

» The Cryptocurrency Crash Is Great News For The Rest of The World. Here's Why
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 11:26 am by PurpleSkyz

» UFO hearing: 400 cases remain 'unidentified'
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 11:22 am by PurpleSkyz

» Nestle is airlifting baby formula to the US from the Netherlands and Switzerland
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 11:14 am by PurpleSkyz

» GASP!!!! ‘Good Morning America’ Admits Covid Booster Shots Can Cause AIDS
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 11:11 am by PurpleSkyz

» Thai govt gives away 1,000,000 cannabis plants, encourages citizens to grow NATURAL medicine
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 10:49 am by PurpleSkyz

» Good People Doing Good Things —
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 10:43 am by PurpleSkyz

» Statistical analysis shows that NOBODY under 60 should take the COVID vaccine
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 10:32 am by PurpleSkyz

» Covid Case/Hosp/Death Rates now highest among Triple Vaxxed in Canada
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 10:28 am by PurpleSkyz

» Deadly Immunity – Government Cover-up of a Mercury/Autism Scandal
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyToday at 10:19 am by PurpleSkyz

» Who made these circles in the Sahara?
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 11:55 am by PurpleSkyz

» Military Shows New UFO Videos to Congress
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 11:50 am by PurpleSkyz

» Why Human DNA Might Be The Product of Another Intelligence
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 10:41 am by PurpleSkyz

» 5G Health Effects Testimony to Mitchell South Dakota Council May 2022
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 10:30 am by PurpleSkyz

» The Ghostly Sounds of Auroras Can Be Heard, Even When They're Invisible
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 9:34 am by PurpleSkyz

» RFK, Jr. to Speak at May 19 ‘Humanity Against Censorship’ Rally
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 9:28 am by PurpleSkyz

» Biden Health Secretary Says He Knew About Baby Formula Crisis Last Year
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 9:15 am by PurpleSkyz

» Rheumatologist: 40% of my 3,000 vaxxed patients reported injury
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 9:10 am by PurpleSkyz

»  The Journey to #OceanStewardship - Natreve x Plastic Bank
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 1:04 am by PurpleSkyz

»  Baby formula factory Abbott and FDA reach agreement to restart production
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 12:56 am by PurpleSkyz

» Do you know someone who died between Mar and December 2020?
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyYesterday at 12:44 am by PurpleSkyz

» 2000 Felons and Zero Justice
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid EmptyMon May 16, 2022 9:33 am by PurpleSkyz

You are not connected. Please login or register

OUT OF MIND » BREAKING NEWS & HOT TOPICS » COVID-19 » NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid

NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid

Go down  Message [Page 1 of 1]

PurpleSkyz

PurpleSkyz
Admin

NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid


Responding to reports of patients relapsing after completing a five-day course of Paxlovid, Pfizer CEO Albert Bourla suggested patients just take more, prompting a rebuke from a U.S. Food and Drug Administration official.

By 
  Julie Comber, Ph.D.  
Link copied
NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid Paxlovid-pfizer-covid-antiviral-pill-feature-800x417


Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.
National Institutes of Health (NIH) researchers said they will investigate how often and why coronavirus levels rebound in some patients who complete a five-day course of Pfizer’s COVID-19 antiviral pill, Paxlovid.
“It is a priority,” Clifford Lane, deputy director for clinical research at the National Institute of Allergy and Infectious Diseases, told Bloomberg. It’s “a pretty urgent thing for us to get a handle on.”
Lane said the agency is discussing with scientists at the Centers for Disease Control and Prevention possible epidemiological and clinical studies to examine post-Paxlovid rebound.
In response to reports of patients relapsing after taking Paxlovid, Pfizer CEO Albert Bourla on Tuesday suggested they take more of the treatment, contrary to the established protocol.
Bourla’s comment prompted a U.S. Food and Drug Administration (FDA) official on Wednesday to contradict Bourla, FiercePharma reported.
John Farley, M.D., director of the Office of Infectious Diseases, in the FDA Updates on Paxlovid for Health Care Providers wrote:
“There is no evidence of benefit at this time for a longer course of treatment (e.g., 10 days rather than the 5 days recommended in the Provider Fact Sheet for Paxlovid) or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course.”
Bloomberg and ABC News reported on accounts of viral rebound after treatment with Paxlovid that were posted on social media or described by physicians and patients.
People described feeling better rapidly after starting the five-day course of Paxlovid, testing negative on a rapid test after treatment and resuming normal activities, only to have their symptoms come roaring back within days of their last dose. Some patients tested positive again.
The only case of viral rebound reported in the medical literature so far is a preprint study released April 26.

1 Million Copies Sold — ‘The Real Anthony Fauci’ — The book that launched a movement. BUY TODAY!  

Pfizer last week issued a press release stating Paxlovid did not prevent COVID-19 infection in people who were exposed to a household member infected with the virus.
The FDA in December 2021, granted Emergency Use Authorization (EUA) for Paxlovid, a combination of nirmatrelvir and ritonavir tablets, for patients at high risk of progressing to severe COVID-19.
This EUA was based on Pfizer’s Phase 2-3 double-blind, randomized, controlled trial. Participants were included in the trial if they had symptomatic COVID-19, were unvaccinated, were not hospitalized, were adults and were at high risk for progression to severe COVID-19.
The trial data, recently published in The New England Journal of Medicine, showed an 89% relative risk reduction of progression to severe COVID-19 for this high-risk group, meaning, those in the trial who took a five-day course of Paxlovid had a lower risk of progressing to severe COVID-19.
However, for those who were already immune to COVID-19, the absolute risk reduction was about 1%.
On the basis of the Pfizer trial data, President Biden in March announced the “Test to Treat” initiative, a plan that allows Americans who test positive for COVID-19 at a pharmacy to get free antiviral pills immediately, including Paxlovid.
The Paxlovid EUA is for high-risk people. In the Test to Treat centers, patients are instructed to bring a list of medications with them and to ask the healthcare provider at the center if they are eligible for oral antiviral treatment.
The Test to Treat healthcare provider will then decide if the patient is at high risk.
As reported in The Defender, the taxpayer-funded initiative is a huge windfall for Pfizer, especially coming on top of the multi-billion-dollar government contracts for the drugmaker’s COVID-19 vaccine.
John Campbell, Ph.D., in the video below pointed out that Pfizer’s Paxlovid trial took place from mid-July to early December 2021, when the Delta variant was dominant.



https://youtu.be/iax-dL7F3qw

The time period during which the trial occurred also is when fewer people had naturally acquired or vaccine-induced immunity to COVID-19, raising questions about whether the $530 five-day treatment is even effective against the newer variants predominant today.
The FDA granted the EUA for children 12 and older and for COVID-19-vaccinated people — even though both groups were excluded from the clinical trials.
Despite concerns about viral rebound, Pfizer executives said the use of Paxlovid has increased by nearly 10-fold in recent weeks, as infection rates across the U.S. rise.
Pfizer foresees $54 billion in global sales this year — $32 billion from its COVID-19 vaccine and $22 billion from Paxlovid.

https://childrenshealthdefense.org/defender/nih-relapse-pfizers-covid-antiviral-pill-paxlovid/
Thanks to: https://childrenshealthdefense.org



  

Back to top  Message [Page 1 of 1]

Permissions in this forum:
You cannot reply to topics in this forum